Halozyme Pulls €2B Acquisition Bid as Evotec Commits to Standalone Strategy
Halozyme has withdrawn its offer to buy biopharmaceutical services firm Evotec for €2 billion, a move that comes after repeated requests to meet with the company to discuss a deal were all turned down. Halozyme, a company with a platform technology for …